Key result
Resveratrol supplementation significantly improved flow-mediated dilation (WMD 1.43%; 95% CI 0.98-1.88; p<.001) and reduced ICAM-1, though VCAM-1, fibrinogen, and PAI-1 did not change.
Why the study?
The study was conducted to quantify the effect of resveratrol supplementation on endothelial function.
Does resveratrol supplementation improve endothelial function?
Meta-Analysis
Does resveratrol supplementation improve endothelial function?
Mean Difference: 1.43 (95% CI 0.98–1.88)
p-value: p=<.001
Resveratrol supplementation significantly improves surrogate markers of endothelial function, including FMD and ICAM-1, suggesting potential cardiovascular benefits.
Supports resveratrol for endothelial health in CVD patients; confirms RCT benefits across 17 studies.
We perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to quantify the effect of resveratrol supplementation on endothelial function. A comprehensive search was performed in electronic databases including PubMed, Scopus, Web of Science, and Cochrane Library up to February 2021 with no limitation in time and language. A meta-analysis of eligible studies was performed using a random-effects model to estimate the pooled effect size of flow-mediated dilation (FMD), intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), fibrinogen, and plasminogen activator inhibitor-1 (PAI-1). In total, 21 arms from 17 studies were included. The meta-analysis results showed that resveratrol significantly change the concentrations of FMD (WMD: 1.43%; 95% CI: 0.98 to 1.88, p < .001) and ICAM-1 (WMD: -7.09 ng/ml, 95% CI: -7.45 to -6.73, p < .001). However, VCAM-1, fibrinogen, and PAI-1 did not change significantly after resveratrol supplementation. In conclusion, the results of this study suggest that resveratrol supplementation can improve endothelial function which could be important, especially in patients with cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Mohammadipoor et al. (2022) reported a meta-analysis. Resveratrol supplementation was evaluated on Flow-mediated dilation (FMD) (WMD 1.43%, 95% CI 0.98 to 1.88, p=<.001). Resveratrol supplementation significantly improved flow-mediated dilation (WMD 1.43%; 95% CI 0.98-1.88; p<.001) and reduced ICAM-1, though VCAM-1, fibrinogen, and PAI-1 did not change.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: